secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-064531
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Q1 2025 net loss $32.1M; cash $103.1M funds ops into Q2 2026
--------------------------------------------------------------------

- Cash, cash equivalents, restricted cash and marketable securities of $103.1M as of March 31, 2025.
- Net loss of $32.1M ($0.42 per share) vs. $31.4M ($0.42) in Q1 2024; R&D expense $28.8M (+5% YoY).
- PRT3789 monotherapy and docetaxel combo dose escalation complete; Phase 2 data expected H2 2025.
- PRT7732 Phase 1 advancing in 5th cohort at 60 mg once daily; initial data anticipated H2 2025.
- KAT6A degrader program targeting candidate nomination in Q2 2025 and IND in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017025064531/0000950170-25-064531-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017025064531/prld-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-064531

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer